Radiochemical Stability: Latest Developments Shaping Modern Radiopharmacy

Introduction

Radiochemical stability has become one of the most important scientific and practical issues in modern radiopharmacy. For many years, stability was often treated as a final checkpoint in the preparation of a radiopharmaceutical. A product would be synthesised, its radiochemical purity measured, and, if it met specification, it would be released for clinical use. That model is no longer sufficient. The latest developments in the field show that radiochemical stability is now being treated as something that must be built into the product from the earliest stages of development.

This shift has emerged because researchers and manufacturers now recognise that stability is influenced by a broad range of interacting factors. These include the radionuclide source, precursor quality, pH, buffer composition, antioxidant or quencher choice, activity concentration, storage conditions, and the timing and method of quality control. As radiopharmaceuticals move further into high-activity therapeutic applications, larger-batch production, and centralised manufacturing, stability has become a decisive factor in determining whether a product is practical, reliable and suitable for wider clinical use.

Moving Beyond the Old View of Stability

The traditional view of radiochemical stability was relatively simple. If a product met the radiochemical purity limit at the time of release, it was often considered fit for purpose. That approach may have been adequate for smaller-scale production or tracers intended for immediate local use, but it is no longer enough for the current direction of radiopharmaceutical development.

Modern radiopharmacy demands more. A product may need to remain stable through synthesis, quality control, dispensing, transport, and administration, sometimes over many hours. In some cases, a radiopharmaceutical must also tolerate high activity concentrations and repeated handling steps without showing meaningful degradation. As a result, stability is no longer being regarded as a single end-point measurement. It is increasingly recognised as a dynamic property that affects the product’s full life cycle.

Lutetium-177 and the Rise of Product-Specific Stability Profiles

One of the most important recent areas of progress has been in lutetium-177-labelled therapeutic radiopharmaceuticals. These agents play a major role in targeted radionuclide therapy, yet newer studies have shown that their stability cannot be explained by one factor alone. Higher bulk activity and greater radiochemical concentration can increase radiolytic stress, which in turn may reduce radiochemical purity over time. Even so, the situation is more complex than a simple activity–degradation relationship.

Different lutetium-177 radiopharmaceuticals behave differently under similar conditions. Some formulations remain chemically robust over extended periods, while others are more vulnerable to degradation after longer hold times. This has important practical consequences. A product that remains stable throughout the working day offers flexibility for transport, dose preparation and delayed administration. One that begins to deteriorate after only a few hours presents a very different operational challenge.

These findings have led to a more tailored understanding of stability. Rather than applying a single broad assumption to all lutetium-177 products, radiopharmacies are increasingly expected to build product-specific stability profiles based on the exact formulation, concentration, and production conditions involved.

The Importance of Radionuclide Source and Precursor Quality

Another important development is the growing appreciation that the quality of radionuclide sources and precursors can directly affect radiochemical stability. In practice, materials may be obtained from different suppliers, and even small differences in composition can influence the behaviour of the final product. Trace metals, carrier content, and other supply-related variables may alter radiolabelling efficiency or promote degradation pathways that are not immediately obvious.

This matters because a process validated with one radionuclide source may not behave in exactly the same way with another. Stability is therefore no longer only a formulation issue. It is also part of a broader quality strategy that includes raw material selection, supplier qualification and careful process control.

This development marks an important step for routine radiopharmacy. It encourages a more complete understanding of the product and reduces the risk of assuming that all starting materials are interchangeable. In an area where product integrity is closely tied to patient care, that is a very important advance.

Progress in Actinium-225 Formulation Science

Targeted alpha therapy has become one of the most active areas of radiopharmaceutical research, and actinium-225 is central to that interest. Yet alpha emitters generate intense local radiolytic stress, making it particularly difficult to maintain radiochemical stability. Recent work has shown that actinium-225-labelled radiopharmaceuticals are highly sensitive to formulation conditions, especially pH and the choice of stabilising agents.

This has led to notable progress in the use of buffer systems and quenchers. Carefully chosen scavengers and excipients can help reduce radiolytic damage and preserve radiochemical purity for longer periods. Such advances are important because they improve the practical usability of actinium-225 products. A formulation that remains chemically intact for a longer period is more compatible with the realities of quality control, preparation, and clinical scheduling.

What is becoming clear is that actinium-225 radiopharmaceuticals cannot rely on generic formulation strategies borrowed from other radionuclides. They require specifically optimised chemistry, with close attention to the conditions that support both efficient labelling and continued stability after synthesis.

Stability and the Role of Analytical Science

A major theme in current research is that stability is not only about preventing degradation but also about accurately measuring it. This has brought analytical science into much sharper focus. If a quality control method is insufficiently sensitive or fails to distinguish between intact product and degradation-related impurities, instability may be underestimated or missed entirely.

As a result, formulation development and analytical development are becoming more closely linked. It is no longer enough to prepare a product that appears stable on paper. The analytical methods used to assess radiochemical purity must also be capable of detecting subtle or time-dependent changes. This is especially important for therapeutic radiopharmaceuticals, where higher activities may generate degradation products that are not captured well by less refined methods.

The latest work in the field shows a growing commitment to better chromatography, improved method validation and more thoughtful timing of quality control measurements. This development is strengthening confidence in shelf-life claims and helping radiopharmacies make more informed release decisions.

Astatine-211 and the Challenge of In Vivo Stability

Astatine-211 continues to attract strong interest as a promising radionuclide for targeted alpha therapy, but its development has long been limited by chemical instability. In many astatine-labelled compounds, the issue is not only radiolysis but also the relative weakness of certain astatine–carbon bonds. This can lead to deastatination in vivo, causing the radionuclide to separate from the targeting vector and accumulate in unintended tissues.

Recent research has brought a more mechanistic understanding to this problem. Rather than relying mainly on empirical screening of different labelling approaches, scientists are now examining how chemical structure influences astatine retention. Greater attention is being given to aromatic substitution patterns, linker design, and neighbouring groups that may support stronger, more durable attachment.

This more rational approach represents a meaningful advance. It suggests that future astatine-211 radiopharmaceuticals may be designed with improved in vivo stability from the outset, rather than adjusted later in response to poor performance. Better in vivo stability would not only improve therapeutic targeting but also reduce off-target uptake and support more reliable dosimetry.

PET Radiopharmaceuticals and Stress Testing

On the positron emission tomography side, one of the clearest developments has been the increasing use of formal stress-testing approaches. In the past, many stability studies focused on routine room-temperature hold periods and fairly standard preparation conditions. Recent work has extended that approach by testing radiopharmaceuticals under a wider range of temperatures and pH conditions, more closely reflecting the methods used in conventional pharmaceutical science.

This is a useful development because it provides a fuller picture of how a product behaves when conditions are not ideal. A radiopharmaceutical may be exposed to temperature fluctuations during handling or transport, and it may encounter slight variations in formulation conditions during routine production. Stress testing helps identify the limits of the formulation and shows how resilient the product really is.

By adopting broader testing strategies, the field is moving towards stronger and more defensible shelf-life claims. This is particularly important for PET tracers that may be produced at one site and distributed to several centres, where reliability over time is essential.

Centralised Production and Distribution

Another important trend is the move towards radiopharmaceutical formulations that support centralised manufacturing and wider distribution. This is especially relevant for fluorine-18-labelled tracers, whose long half-life permits transport over a regional network, provided the final product remains chemically stable.

Recent developments show that with careful formulation design, including the right choice of antioxidants, buffers and excipients, fluorine-18 radiopharmaceuticals can retain high radiochemical purity for many hours after synthesis. This has practical implications that extend well beyond the laboratory. Greater stability can support larger-batch production, reduce waste, improve scheduling flexibility and increase access to imaging agents across multiple sites.

This also highlights the importance of apparently small formulation choices. A single excipient or buffer component may determine whether a radiopharmaceutical is suitable only for immediate local use or whether it can be distributed more widely as a routine clinical product. Stability, in this sense, has become a bridge between chemistry and healthcare delivery.

From Technical Detail to Strategic Priority

Taken together, these developments show that radiochemical stability is no longer a narrow technical matter. It has become a strategic priority across radiopharmaceutical development. The older assumption that instability could usually be controlled by limiting activity and adding a general antioxidant is proving too simplistic for current needs.

Today, stability is understood as an integrated property that links chemistry, analytics, raw materials, manufacturing and clinical workflow. Product-specific behaviour, radionuclide source, precursor quality, pH, formulation additives, storage temperature and analytical timing can all shape the final stability profile in ways that matter for patient care.

This broader understanding is helping to reshape how radiopharmaceuticals are developed. Rather than trying to correct degradation problems late in the process, researchers are increasingly designing products with stability in mind from the beginning. That is a more efficient and scientifically grounded route to clinical translation.

Implications for the Future of Radiopharmacy

The practical implications of these changes are considerable. Shelf-life assignment is becoming more evidence-based and more specific to the individual product. Supplier qualification is likely to play a larger role in future stability programmes. Formulation science is gaining greater importance, especially for therapeutic radiopharmaceuticals and alpha emitters. At the same time, analytical methods are being refined to characterise degradation more accurately and consistently.

This means that the radiopharmaceuticals most likely to succeed in routine clinical practice will be those developed with a clear understanding of stability from the outset. Stability will increasingly determine not only whether a product passes quality control, but also whether it can be manufactured at scale, transported safely, scheduled efficiently and used with confidence in patients.

Conclusion

The latest developments in radiochemical stability show a field that is becoming more mature, more predictive and more closely aligned with modern pharmaceutical science. Work on lutetium-177 has shown that stability depends on far more than activity alone. Research involving actinium-225 has clarified the importance of pH control and tailored quencher systems. Astatine-211 studies are improving the understanding of in vivo chemical integrity. PET radiopharmaceutical development is adopting broader stress-testing strategies, while newer fluorine-18 formulations are being designed to support centralised production and wider distribution.

All of these changes point in the same direction. Radiochemical stability is no longer a secondary technical issue considered only at the point of release. It is now a central determinant of whether a radiopharmaceutical can successfully transition from development to dependable routine clinical care.

Suggested Reading

• How New MRI Contrast Agents Are Transforming Medical Imaging
• Carbon-14 Radiolabelling Is Entering a New Era in Drug Development
• Recent Advances in the Stability and Design of Carbon-14 Labelled Compounds
• Carbon-14 Stability in Active Pharmaceutical Ingredients
• Radiopharmacy: Harnessing Radioactive Compounds for Diagnosis and Treatment

References

Hunt W, Long M, Kamil U, Kellapatha S, Noonan W, Roselt PD, et al. Multifactorial analysis of radiochemical purity in high-activity 177Lu-labeled theranostics: impact of precursor source, 177Lu form, and production parameters. EJNMMI Radiopharm Chem. 2025;10(1):47. Available from: https://doi.org/10.1186/s41181-025-00372-5

Hooijman EL, de Jong JR, Ntihabose CM, Bruchertseifer F, Morgenstern A, Seimbille Y, et al. Ac-225 radiochemistry through the lens of [225Ac]Ac-DOTA-TATE. EJNMMI Radiopharm Chem. 2025;10(1):9. Available from: https://doi.org/10.1186/s41181-025-00332-z

Storms W, Celen S, Maes J, Serdons K, Goffin K, De Groot T, et al. cGMP-compliant high-yield automated production of [18F]AlF-FAPI-74: optimization of quality control and evaluation of molar dose impact. EJNMMI Radiopharm Chem. 2025;11(1):3. Available from: https://doi.org/10.1186/s41181-025-00411-1

Müller M, et al. Astatine-211—towards in vivo stable astatine-211 labeled radiopharmaceuticals and their (pre)clinical applications. Med Res Rev. 2026;46:203-237. Available from: https://doi.org/10.1002/med.70008

Zhao T, et al. Enhancing the stability of 211At radiopharmaceuticals. ACS Med Chem Lett. 2025. Available from: https://doi.org/10.1021/acsmedchemlett.5c00102

Fouinneteau R, et al. Ortho-functionalization of a 211At-labeled aryl compound provides stabilization of the C-At bond against oxidative dehalogenation. Sci Rep. 2025. Available from: https://doi.org/10.1038/s41598-025-01162-4

Vanermen M, Ligeour M, Oliveira MC, et al. Astatine-211 radiolabelling chemistry: from basics to advanced biological applications. EJNMMI Radiopharm Chem. 2024;9:69. Available from: https://doi.org/10.1186/s41181-024-00298-4

Hooijman EL, Radchenko V, Ling SW, Konijnenberg M, Brabander T, Koolen SLW, et al. Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives. EJNMMI Radiopharm Chem. 2024;9(1):9. Available from: https://doi.org/10.1186/s41181-024-00239-1

Disclaimer: This article is intended for general informational and educational purposes only and does not constitute scientific, regulatory, manufacturing, or clinical advice. While every effort has been made to ensure accuracy at the time of publication, developments in radiopharmacy may evolve rapidly, and readers should consult relevant specialists, official guidance, and validated sources before making technical, operational, or patient-care decisions.